Side-by-side comparison of AI visibility scores, market position, and capabilities
Israeli AI drug discovery company raised $25M from Bessemer; 40+ active programs; CEO co-patented CRISPR technology with Jennifer Doudna; ML platform combining target identification, hit generation, and lead optimization for oncology and immunology therapeutics.
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.\n\nConverge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.\n\nConverge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery.
Alphabet/DeepMind drug discovery spinoff raised $600M from Thrive Capital; Drug Design Engine doubled AlphaFold3 accuracy for molecular design; partnering with major pharma; preparing first clinical trials from AI-directed drug pipeline across multiple therapeutic areas.
Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection. Founded in 2021 under CEO Demis Hassabis's vision of using AI to accelerate medicine, Isomorphic operates with the scientific resources and computational infrastructure of DeepMind while functioning as a standalone drug discovery organization. The company's founding mission is to use AI not merely as a tool to assist drug hunters, but as the primary engine of drug design — replacing the slow, expensive, and largely empirical process of traditional medicinal chemistry with AI-directed molecular engineering.\n\nIsomorphic's core platform is the Drug Design Engine, a proprietary AI system built on top of AlphaFold architecture. The Drug Design Engine has achieved landmark performance results, reportedly doubling the accuracy of AlphaFold3 at predicting how small molecules bind to their protein targets — the fundamental problem in structure-based drug design. This capability enables Isomorphic to computationally design molecules predicted to bind their targets with far greater precision than conventional methods, potentially eliminating many of the expensive iterative cycles that make drug development so slow. The company has also established major pharma partnerships with Eli Lilly and Novartis to co-develop drug candidates across multiple therapeutic areas.\n\nIsomorphic raised $600M from Thrive Capital in 2024–2025, bringing substantial private capital alongside its Alphabet backing to accelerate pipeline development. As of 2026, the company is preparing for its first clinical trials — a critical milestone that will test whether its computational drug design predictions translate into human efficacy. With AlphaFold-derived technology at its core, partnerships with two of the world's largest pharmaceutical companies, and over half a billion in funding, Isomorphic Labs represents the most credentialed and well-resourced pure-play AI drug discovery company in existence.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.